CureVac
CureVac N.V. is a German biopharmaceutical company that creates therapies based on messenger RNA (mRNA). It is headquartered in Tübingen, Germany. The company
CureVac N.V. is a German biopharmaceutical company that creates therapies based on messenger RNA (mRNA). It is headquartered in Tübingen, Germany. The company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee.
CureVac had about 240 employees in November 2015.[1]
The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases.[2]
References
- ↑ "Gates, Hopp back $110M megaround for CureVac's mRNA work".
- ↑ Carroll, John (18 October 2017). "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines". endpts.com.
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.